Definium director granted RSUs and stock options

Definium Therapeutics director Suzanne Louise Bruhn received equity compensation on common shares.

Rhea-AI Filing Summary

Definium Therapeutics director Suzanne Louise Bruhn received equity compensation on common shares. She was granted 4,666 restricted stock units, each representing one future common share, and a stock option for 19,188 common shares at an exercise price of $24.11 per share.

The RSUs and the stock option each vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with remaining unvested awards vesting immediately before the company’s next annual meeting if it occurs within the first year, subject to her continued service. Following these grants, she directly holds 24,289 common shares.

Insider Trade Summary

Grant/Award: 23,854 shares

Grant/Award 2 txns

Insider Bruhn Suzanne Louise

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,188	$0.00	$0.00
Grant/Award	Common Shares	4,666	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,188 contracts (Direct); Common Shares — 24,289 shares (Direct)

Footnotes (2)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
2. F2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

RSU grant: 4,666 units Stock option grant: 19,188 shares Option exercise price: $24.11 per share +4 more

7 metrics

RSU grant 4,666 units Restricted stock units granted on June 11, 2026

Stock option grant 19,188 shares Stock Option (Right to Buy) granted on June 11, 2026

Option exercise price $24.11 per share Conversion or exercise price for stock option

Option expiration June 10, 2036 Expiration date for stock option

Shares after transaction 24,289 shares Total common shares directly held following grants

RSU vesting schedule 1/12 monthly RSUs vest monthly with potential acceleration before next annual meeting

Option vesting schedule 1/12 monthly Stock options vest monthly with potential acceleration before next annual meeting

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), contingent right, vests and becomes exercisable, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"

contingent right financial

"Each RSU represents a contingent right to receive one common share of the Issuer."

vests and becomes exercisable financial

"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"

annual meeting financial

"immediately prior to the Issuer's annual meeting following the date of grant"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Definium Therapeutics (DFTX) director Suzanne Bruhn receive?

Suzanne Bruhn received 4,666 restricted stock units and a stock option for 19,188 common shares at an exercise price of $24.11 per share. These awards are part of her director compensation package and do not represent an open-market share purchase.

How do Suzanne Bruhn’s new RSUs at Definium Therapeutics (DFTX) vest?

The 4,666 restricted stock units vest in 12 equal monthly installments starting from the grant date. Any remaining unvested RSUs vest immediately before the next annual shareholder meeting if it occurs within one year, assuming she continues serving as a director.

What are the vesting terms of Suzanne Bruhn’s stock options at Definium Therapeutics (DFTX)?

The stock option for 19,188 common shares vests in 12 equal monthly installments from the grant date. If the next annual meeting occurs within one year, any unvested portion vests immediately before that meeting, contingent on her continued service with the company.

What is the exercise price and expiration date of Suzanne Bruhn’s Definium Therapeutics (DFTX) stock options?

Suzanne Bruhn’s stock options have an exercise price of $24.11 per share and expire on June 10, 2036. She may exercise vested portions any time before expiration, subject to plan terms and her continued service conditions.

How many Definium Therapeutics (DFTX) common shares does Suzanne Bruhn hold after these grants?

After the equity grants, Suzanne Bruhn directly holds 24,289 common shares. This total includes the 4,666 restricted stock units that convert into common shares as they vest, in addition to her previously held shares and any other directly owned common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruhn Suzanne Louise

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/11/2026		A		4,666(1)	A	$0.00	24,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$24.11	06/11/2026		A		19,188		(2)	06/10/2036	Common Shares	19,188	$0	19,188	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Mark Sullivan, Attorney-in-Fact for Suzanne Bruhn	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)